𝛼SK or Search

ENTITY

Cloudbreak Pharma (2592 HK)

4

Analysis

Health Care • United States

Cloudbreak Pharma is a clinical-stage ophthalmology biotechnology company dedicated to developing novel and differentiated treatments for eye diseases, leveraging its proprietary Multi-Kinase Inhibitor (MKI) platform. Its pipeline includes lead candidates such as CBT-001 for pterygium and CBT-004 for pinguecula, both in late-stage clinical trials. The company was founded in 2015 and is headquartered in Irvine, California, USA, with operations also in Mainland China and Hong Kong.

more

Refresh

Exchange Announcement • 30 Sep 2026 21:50

Formation Of An Independent Special Committee; Delay In Publication And Despatch Of 2026 Interim Report; And Continued Suspension Of Trading

Exchange Announcement • 23 Sep 2026 22:11

List Of Directors And Their Roles And Functions

Exchange Announcement • 23 Sep 2026 22:07

Appointment Of Independent Non-Executive Directors And Continued Suspension Of Trading

Exchange Announcement • 18 Sep 2026 22:43

Business Updates And Supplemental Announcement In Relation To 2025 Annual Report

Exchange Announcement • 18 Sep 2026 22:40

Suspension Of Trading

Copyright © 2022 Smartkarma Innovations Pte Ltd. All Rights Reserved. v3.70.4

x